Cargando…

Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer

BACKGROUND: Progestin is used for fertility-sparing treatment in cases of endometrial cancer (EC). Progestin can induce hyperprolactinemia by increasing pituitary secretion and endometrial decidualization. However, progestin induces prolactin (PRL) secretion, which stimulates cell proliferation and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Wenjing, Mitsuhashi, Akira, Kobayashi, Tatsuya, Shozu, Makio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277913/ https://www.ncbi.nlm.nih.gov/pubmed/35820883 http://dx.doi.org/10.1186/s12885-022-09858-w

Ejemplares similares

Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
por: Mitsuhashi, Akira, et al.
Publicado: (2020)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer
por: Hanawa, Shinsuke, et al.
Publicado: (2018)

Inhibitory Effects of Medroxyprogesterone Acetate on Mouse Endometrial Carcinogenesis
por: Niwa, Kenji, et al.
Publicado: (1995)

Time-lapse monitoring of fertilized human oocytes focused on the incidence of 0PN embryos in conventional in vitro fertilization cycles
por: Kobayashi, Tatsuya, et al.
Publicado: (2021)

Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
por: Yamagami, Wataru, et al.
Publicado: (2018)

Prolactin Enhances the Proliferation of Proliferative Endometrial Glandular Cells and Endometrial Cancer Cells
por: Yamaguchi, Munekage, et al.
Publicado: (2019)

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma
por: Jing, Chu-Yu, et al.
Publicado: (2022)

Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
por: Wang, Ding-Ran
Publicado: (2023)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Development of localized cul-de-sac endometrioid carcinoma associated with deep infiltrating endometriosis during remission of early endometrial cancer
por: Seki, Kumiko, et al.
Publicado: (2019)

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014)

Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro
por: Patel, Mickey V., et al.
Publicado: (2021)

Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization
por: Guo, Haiyan, et al.
Publicado: (2017)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
por: Bilir, Ayhan, et al.
Publicado: (2011)

Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
por: Faigenbaum, Raya, et al.
Publicado: (2013)

Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
por: Ushijima, Kimio, et al.
Publicado: (2023)

Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis
por: Kobayashi, Tatsuya, et al.
Publicado: (2022)

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971)

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
por: Potkul, Ronald K, et al.
Publicado: (2016)

Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells
por: Cao, Wenjiao, et al.
Publicado: (2019)

Fertility-sparing treatment in women with endometrial cancer
por: Won, Seyeon, et al.
Publicado: (2020)

Fertility-sparing treatment for patients with endometrial carcinoma
por: Ind, T
Publicado: (2023)

The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis–Specific Host Immunity Through the Glucocorticoid Receptor
por: Tomasicchio, Michele, et al.
Publicado: (2019)

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma
por: SATO, MASAKAZU, et al.
Publicado: (2016)

Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis.
por: Russo, I. H., et al.
Publicado: (1989)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
por: Chen, Junyu, et al.
Publicado: (2022)

Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy
por: Ga, Hiromi, et al.
Publicado: (2023)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Changes in Hematologic Parameters during Treatment with Medroxyprogesterone Acetate for Breast Cancer
por: Yamamoto, Hitoshi, et al.
Publicado: (1991)

Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls
por: Kesterson, Joshua P., et al.
Publicado: (2012)

Breast cancer in the setting of fertility-sparing treatment for endometrial cancer
por: Moss, Haley A., et al.
Publicado: (2014)

Pushing the envelope: expanding fertility sparing treatment of endometrial cancer
por: Stewart, Katherine Ikard, et al.
Publicado: (2020)

Carbon-ion radiotherapy for inoperable endometrial carcinoma
por: Irie, Daisuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gs37spdbs1o7rh4g40ohs1jqhl